FINWIRES · TerminalLIVE
FINWIRES

Allogene Therapeutics Cleared to Expand B-Cell Lymphoma Treatment Trial in South Korea, Australia

By

Allogene Therapeutics (ALLO) said Tuesday it has received clearance from regulators in South Korea and Australia to expand its pivotal phase 2 study evaluating cemacabtagene ansegedleucel in first-line consolidation treatment for patients with large B-cell lymphoma into those two countries.

With the clearances, the study is set to expand to more than 80 global sites from more than 60 sites currently in North America, the company said.

The study is expected to enroll about 220 patients by the end of 2027, with an interim analysis of event-free survival anticipated in mid-2027 and the primary analysis in mid-2028, according to a statement.

Positive results from the study could support a biologics license application submission, Allogene said.

Price: $2.31, Change: $-0.12, Percent Change: -4.75%

Related Articles

Wire

IDP Education to Introduce Malaysia as Study Destination

IDP Education (ASX:IEL) expanded its range of study destinations by supporting students to study in Malaysia, according to a Tuesday statement.The company cited changing student preferences as a reason for the move, with growing demand for new destinations offering strong education quality, career outcomes, and affordable study options.The initial rollout will focus on a select number of markets as part of a phased pilot.IDP Education's shares declined 1% in recent trading on Tuesday.

ASX:IEL
Wire

Infratil Says Moody's Assigns CDC Data Centers 'Baa2' Rating, Stable Outlook

Infratil (NZE:IFT, ASX:IFT) said Moody's Ratings has assigned CDC Data Centers Australia its first public investment grade credit rating of "Baa2" with a stable outlook, according to Tuesday filings with the Australian and New Zealand bourses.The rating reflects CDC's strong financial position, stable long-term contracted revenues, and exceptionally long lease durations averaging 28.4 years, per the filing.The rating will enable CDC to improve access to capital markets, supporting further large-scale infrastructure development driven by rising demand from government, hyperscale cloud providers, and critical industries, the filing added.The company's Kiwi shares shed 1% in recent Tuesday trade.

ASX:IFTNZE:IFT
Wire

Spruce Biosciences Begins Public Offering of Stock, Prefunded Warrants; Shares Fall After Hours

Spruce Biosciences (SPRB) said late Monday it commenced an underwritten public offering of common shares or related prefunded warrants.The company expects to grant underwriters a 30-day option to buy up to 15% more stock at the public offering price, less underwriting discounts and commissions.The offering is subject to market and other conditions, Spruce said.Spruce shares fell 13% in after-hours trading.

$SPRB